Table 2.

Characteristics of the cohort of 11 CVID patients with lymphoma (M, Male; F, Female; LYM, Lymphadenopathy; SPLE, Splenomegaly; ITP, Idiopathic thrombocytopenic purpura; RTI, Respiratory tract infections; DBLCL lymphoma, Diffuse large B-cell lymphoma; MALT lymphoma, Mucosa-associated lymphoid tissue lymphoma; PTCL, Peripheral T-cell lymphoma; N/A, not applicable; Y, Yes; N, No; chemotherapeutic regimens are described in the results).

Patient Nr.	Gender	Age at diagnosis of CVID	Manifestation	IgG serum level	Age at diagnosis of lymphoma	Type of lymphoma	Cause of death	Survival interval	Staging	Therapy
1	M	35 years	RTI	1.9 g/l	57 years	T lymphoma	Infection	0 month	Died before staging	Died before treatment
2	M	53 years	LYM, SPLE	1.15 g/l	64 years	HL	Enteropathy	36 months	IVB	BEACOPP
3	F	41 years	ITP	3.89 g/l	58 years	HL	Alive	4 months	IIA	R-CHOP
4	M	18 years	RTI	2.43 g/l	45 years	DBLCL lymphoma	Alive	9 months	IIA	R-CHOP
5	M	39 years	LYM, SPLE	0.03 g/l	35 years	DBLCL lymphoma	Alive	96 months	IVB	R-CHOP
6	M	37 years	ITP	4.1 g/l	40 years	HL	Alive	12 months	IVA	R-CHOP
7	M	36 years	RTI	4.1 g/l	42 years	HL	Alive	6 months	IIIB	eBEACOPP
8	M	26 years	ITP	4.88 g/l	36 years	Burkitt lymphoma	Alive	25 months	IIIA	B-NHL GMALL
9	F	25 years	RTI	2.88 g/l	36 years	MALT lymphoma	Alive	145 months	IVA	R-CHOP
10	M	11 years	RTI	4.48 g/l	11 years	HL	Alive	204 months	IIIA	DBVE-PC
11	M	25 years	RTI	1.76 g/l	30 years	PTCL	Infection	9 months	IVA	CHOP